A phase I clinical trial of CHM 2101 in patients with Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer
Latest Information Update: 09 Dec 2021
At a glance
- Drugs CHM 2101 (Primary)
- Indications Colorectal cancer; Gastric cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; First in man
- 09 Dec 2021 New trial record
- 30 Nov 2021 According to a Chimeric Therapeutics media release, this trial is planned to initiate in 2022.